NIH R01 · 2024
Modulating growth, progression and metastasis in breast cancer by inhibiting MDA-9
Despite therapeutic advances, the 5-year survival rate from metastatic triple negative breast cancer (TNBC) has not improved significantly for 30 years. As such, significant benefits to patients with advanced breast cancer will result by developing novel therapies, which target advanced metastatic breast cancer. To address this need we screened metastatic cancers for genes which could contribute to metastasis. From this screen we identified MDA-9/Syntenin-1/Sydecan Binding Protein (MDA-9) as a regulator of cancer cell metastasis. Published and preliminary studies using several mouse models of metastasis confirm that inhibiting MDA-9 prevents metastasis and sensitizes progressive metastatic…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.